Intelligence Report · ~12 min read
GSK Intelligence Report
Generated from 3 signals · 7 evidence sources
Type
Company Intelligence ReportGenerated
Jun 16, 2026
Confidence
Moderate Confidence · 63%
Evidence
11 items
Sources
17
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
GSK maintains an active intelligence profile across Infectious Disease, Pneumococcal Vaccine, Influenza, Psychiatry, PTSD. 3 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 84% across 7 tracked sources. Highest-priority development: Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3. Portfolio development. Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3 is an owned GSK portfolio development in Infectious Disease · Pneumococcal Vaccine.
Key Developments
Material intelligence events ranked by strategic relevance.
- investigateJun 16, 2026
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine · opportunity score 31
View detail - portfolio
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Phase III success
View detail - portfolio
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Phase III success
View detail - regulatory
October - December 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
July - September 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
January - March 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans
Regulatory precedent may inform portfolio positioning
View detail - regulatory
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
[ANZEN]Revisions of PRECAUTIONS: Donanemab(genetical recombination) , etc.
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 83 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Low Confidence · 0%Phase III success
Source: Humanexa Signals, Pfizer, Portfolio
View evidencePfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Low Confidence · 0%Phase III success
Source: PubMed, Pfizer, Portfolio
View evidenceOctober - December 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceJuly - September 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceJanuary - March 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFinal Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceNew Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence[ANZEN]Revisions of PRECAUTIONS: Donanemab(genetical recombination) , etc.
Moderate Confidence · 83%Regulatory precedent may inform portfolio positioning
Source: PMDA, PMDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine
- GSK's AS03-adjuvanted H5N8 vaccine shows promising immunogenicity and safety in Phase 1/2 trial
Infectious Disease · Influenza
- Study Compares PE Therapy, Pharmacotherapy, and Combination for PTSD in Veterans
Psychiatry · PTSD